-+ 0.00%
-+ 0.00%
-+ 0.00%
Shanghai Laishi announced that the wholly-owned subsidiary Guangxi Laishi previously disclosed that the application for clinical trial of protein C was accepted. Recently, it received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and was approved to carry out clinical trials to treat patients with severe congenital protein C deficiency. This product still needs to be clinically tested and reviewed and approved by the State Drug Administration before it can be produced and marketed; there is uncertainty about the development, progress and results of clinical trials and the future market competition situation.
Share
Listen to the news
Shanghai Laishi announced that the wholly-owned subsidiary Guangxi Laishi previously disclosed that the application for clinical trial of protein C was accepted. Recently, it received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and was approved to carry out clinical trials to treat patients with severe congenital protein C deficiency. This product still needs to be clinically tested and reviewed and approved by the State Drug Administration before it can be produced and marketed; there is uncertainty about the development, progress and results of clinical trials and the future market competition situation.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending